PO-HAN LINLin C.-C.Yang H.-I.Li L.-Y.Bai L.-Y.Chiu C.-F.Liao Y.-M.Lin C.-Y.Hsieh C.-Y.Lin C.-Y.Ho C.-M.Yang S.-F.Peng C.-T.Tsai F.-J.Yeh S.-P.2022-03-102022-03-1020130145-2126https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872932688&doi=10.1016%2fj.leukres.2012.10.005&partnerID=40&md5=e0523545c36ed9cbb7e1b518cec07f46https://scholars.lib.ntu.edu.tw/handle/123456789/596936The FLT3 gene with internal tandem duplication (ITD) is a poor prognostic factor in patients with acute myeloid leukemia (AML), and the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) for AML patients with FLT3-ITD is controversial. We examined 122 AML patients; 34 patients had FLT3-ITD and 39 patients received allogeneic HSCT. The median overall survival (OS) of patients with wt. FLT3/nonHSCT, wt. FLT3/HSCT, FLT3-ITD/nonHSCT and FLT3-ITD/HSCT was 40.7 months, 53.4 months, 9.8 months and not reached, respectively (p=0.006). Compared to the wt. FLT3/nonHSCT patients, the hazard ratio (95% CI) of OS for wt. FLT3/HSCT, FLT3-ITD/nonHSCT and FLT3-ITD/HSCT was 1.39 (0.61-3.18), 3.57 (1.58-8.10) and 0.40 (0.11-1.59), respectively, after adjustment of age, sex, WBC, LDH, karyotype, NPM, and FAB classification. This result indicated that patients with FLT3-ITD/nonHSCT had a significantly worse outcome, but allogeneic HSCT improved the prognosis for patients with FLT3-ITD. ? 2012 Elsevier Ltd.Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; FLT3[SDGs]SDG3aciclovir; anthracycline; busulfan; CD135 antigen; ciprofloxacin; cotrimoxazole; cyclophosphamide; cyclosporin; cytarabine; etoposide; fluconazole; fludarabine; granulocyte colony stimulating factor; methotrexate; mitoxantrone; mycophenolic acid 2 morpholinoethyl ester; thymocyte antibody; acute granulocytic leukemia; adolescent; adult; age; aged; allogeneic hematopoietic stem cell transplantation; article; cancer recurrence; cell proliferation; cell survival; child; controlled study; disease free survival; drug megadose; female; FLT3 gene; gender; gene duplication; gene mutation; graft versus host reaction; hazard ratio; human; immunophenotyping; infection; infection prevention; internal tandem duplication; karyotype; leukocyte count; major clinical study; male; morphology; myeloablative conditioning; overall survival; priority journal; retrospective study; school child; Adolescent; Adult; Aged; Child; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Tandem Repeat Sequences; Transplantation, Homologous; Young Adultjournal article10.1016/j.leukres.2012.10.005232763952-s2.0-84872932688